- Practice Areas
- Dangerous Drugs
- Defective Medical Devices
- Attorney Referrals
Home / Dangerous-drugs / Onglyza
A United States Food and Drug Administration (FDA) advisory committee has raised red flags regarding two dipeptidyl peptidase-4 inhibitors: Onglyza (saxagliptin, Bristol-Myers Squibb/AstraZeneca) and Nesina (algoliptin, Takeda Pharmaceuticals).
The FDA panelists noted that patients taking this class of diabetes medication had a 27 percent increase in the rate of hospitalization for heart failure. They further established that there was a potential for an increased risk of death overall, regardless of cause.
Speak with an Alexander Shunnarah Personal Injury Attorneys today to learn about your legal rights, and if you are eligible for compensation.
Patients with diabetes may feel as though they are faced with a gauntlet of choices: take a medication and risk complications or refrain from medicating and risk uncontrolled blood sugar levels. At Alexander Shunnarah Personal Injury Attorneys, we understand how frustrating it can be to feel like a victim and we’re dedicated to empowering patients and their families by helping them make an informed decision on whether filing an Onglyza lawsuit is right for them.